AI Can Develop Personalised MRNA Cancer Vaccine In 48 Hours: Oracle’s Larry Ellison

New Delhi:  Artificial Intelligence (AI) can help develop a customised vaccine against cancer for an individual in just 48 hours, said Oracle chairman Larry Ellison.

At the launch of the Stargate Project in the White House, Ellison said that advancements in AI could revolutionise healthcare and declared that AI will soon design personalised mRNA vaccines for every individual to fight cancer, which can be produced by robotic systems.

He said that since little fragments of tumor float in the blood, AI can help detect the cancer early. Then, with the help of gene sequencing via a simple blood test, a vaccine can be developed to fight against that cancer.

“Little fragments of those tumors float around in your blood. So you can do early cancer detection. If you can do it using AI, you can do early cancer detection with a blood test and using AI to look at the blood test. Once we gene sequence that cancer tumour, we can then vaccinate the person. The design of the vaccine for every individual to vaccinate them against that cancer,” he explained.

Ellison added, “You can make that mRNA vaccine, robotically and using AI in 48 hours. So imagine early cancer detection, the development of a vaccine for your particular cancer aimed at you and have that vaccine in 48 hours – this is the promise of AI.”

President Donald Trump announced an investment of $100 billion in artificial intelligence infrastructure in the US, funded through a joint venture called the Stargate Project, with the aim of increasing it to $500 billion over the course of four years.

The initial equity funders are SoftBank, OpenAI, and MGX, with SoftBank and OpenAI as the lead partners for Stargate. Arm, Microsoft, Nvidia, Oracle, and OpenAI are the project’s “key initial technology partners.”

What is an mRNA vaccine?

An mRNA vaccine uses a small fragment of messenger RNA (a molecule that carries specific instructions from DNA) to instruct the body’s cells to produce a specific protein, triggering an immune response.

This helps the immune system to recognise and attack the cancer cells, teaching the body to target the disease. These vaccines are safe, and can be rapidly developed.

Related Posts

  • Pharma
  • February 17, 2025
  • 74 views
GSK Pharma shares gain 20% following strong Q3FY25 results

GSK Pharma shares gained by 20 percent on Monday, February 17, as brokerages like ICICI Securities and Motilal Oswal continue to maintain positive rating of the stock. GlaxoSmithKline Pharmaceuticals Ltd…

  • Pharma
  • February 17, 2025
  • 69 views
Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

Shares of Glenmark Pharmaceuticals Ltd rose 4% on February 17 after the firm gave a strong guidance for FY26 and it returned to black in the December quarter. The drugmaker…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Wow! What a Change of Heart in Practitioners of Allopathy!

Wow! What a Change of Heart in Practitioners of Allopathy!

GSK Pharma shares gain 20% following strong Q3FY25 results

GSK Pharma shares gain 20% following strong Q3FY25 results

Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

US Tariffs on pharma: What are the potential impact on Indian drugmakers

US Tariffs on pharma: What are the potential impact on Indian drugmakers

Twin Health bats a1000 before enters Digital Health NY 100

Twin Health bats a1000 before enters Digital Health NY 100

US tariff jitters rock pharma stocks; Sun Pharma, Lupin, Dr Reddy’s slump 2-4%

US tariff jitters rock pharma stocks; Sun Pharma, Lupin, Dr Reddy’s slump 2-4%